Heluoxintu is a cell therapy platform developer, focusing on iPSC directed differentiation, gene editing, large-scale cell product preparation and cell therapy technology development, and has developed a general cell therapy platform and a blood system anuclear cell preparation platform. Recently, Heluoxintu has obtained tens of millions of yuan in angel round financing led by Furong Investment. The funds raised in this round will be used to further promote the company’s product pipeline research and development and build new technology platforms.
This article is transferred from: https://www.itjuzi.com/investevent/13795727
This site is only for collection, and the copyright belongs to the original author.